SCHEMBL30765490

SCHEMBL30765490

CCOP(=O)(COc1ccc(-c2ncc(NCCCc3ccccc3)c(=O)n2CC(=O)OC(C)(C)C)cc1)OCC

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ELANE P08246 11/20 0.39
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 1/20 0.38
ADORA3 P0DMS8 2/20 0.37
ADORA2B P29275 2/20 0.37
F2 P00734 1/20 0.37
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
SLC2A1 P11166 1/20 0.35
ASPH Q12797 1/20 0.35
RIOX2 Q8IUF8 1/20 0.35
KDM8 Q8N371 1/20 0.35
S1PR4 O95977 2/20 0.34
S1PR1 P21453 2/20 0.34
S1PR3 Q99500 2/20 0.34
S1PR5 Q9H228 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765980 0.88 ELANE (0.39) ELANEKDM4EALDH1A1F2TP53
SCHEMBL30765994 0.86 ELANE (0.46) ELANEKDM4EALDH1A1F2ASPH
SCHEMBL30765457 0.85 ELANE (0.43) ELANEKDM4EALDH1A1F2ASPH
SCHEMBL30765868 0.85 F2 (0.42) ELANEKDM4EALDH1A1F2SLC2A1
SCHEMBL30765773 0.84 ELANE (0.41) ELANEKDM4EALDH1A1F2SLC2A1
SCHEMBL30765873 0.83 KDM4E (0.41) ELANEKDM4EALDH1A1F2ASPH
SCHEMBL30765501 0.81 ELANE (0.44) ELANEKDM4EALDH1A1F2SLC2A1
SCHEMBL30765914 0.81 ELANE (0.39) ELANEKDM4EALDH1A1F2SLC2A1
SCHEMBL23460649 0.81 ELANE (0.47) ELANEKDM4EALDH1A1F2ASPH
SCHEMBL30766090 0.81 ELANE (0.39) ELANEKDM4EALDH1A1F2SLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed